EUROPEAN HEMATOLOGY ASSOCIATION

24th Congress of EHA

 

June 13-16, 2019 Amsterdam
Close
N. Poster
Poster title
Applicant name
Status
  153-PF MLL-AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER-PROMOTER INTERACTIONS eva hortas Received Received
  158-PF TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520 Matteo Marchesini Received Received
  162-PF FREQUENCY AND PROGNOSTIC IMPACT OF ZEB2 H1038/Q1072 MUTATIONS IN CHILDHOOD B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA Marketa Zaliova Received Received
  163-PF TARGETING LYSOSOMES AS A POTENTIAL THERAPEUTIC APPROACH FOR T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA Antonia Mulet Received Received
  170-PF ETV6/RUNX1 FUSION GENE ABROGATION DECREASE THE ONCOGENIC POTENCIAL OF TUMORS CELLS IN A PRECLINICAL MODEL OF ACUTE LYMPHOBLASTIC LEUKEMIA Adrián Montaño Received Received
  174-PF GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL Sabina Chiaretti Received Received
  177-PF NATION-WIDE PROSPECTIVE, REAL-TIME MONITORING OF PEGYLATED E.COLI AND ERWINIA ASPARAGINASE THERAPY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA IN BELGIUM veerle Mondelaers Received Received
  179-PF DIFFERENT IMPACT OF BCR BREAKPOINT ON THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FROM DIFFERENT GRAFT SOURCE FOR PHALL IN THE ERA OF TKI Satoshi Nishiwaki Received Received
  182-PF CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL) Jose Maria Ribera Santasusana Received Received
  184-PF EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY. Akio Shigematsu Received Received
  188-PF NGS COMBINED WITH ASO REAL-TIME PCR BASED MRD DETECTION ASSAY FOR PEDIATRIC ALL PATIENTS Katerina Nicolaou Received Received
  189-PF APPROPRIATE INTERVAL OF MONITORING FOR DETECTION OF MOLECULAR RELAPSE AFTER STOP OF TKI IN PHALLIN PH ALL CALCULATING BY MRD KINETICS KOICHI MIYAMURA Received Received
  204-PF TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT BARBARA DEPRETER Received Received
  206-PF DUAL TARGETING OF LYSOSOMES AND MITOCHONDRIA BY ANTIHISTAMINES TO ERADICATE LEUKEMIC CELLS Josep Maria Cornet-Masana Received Received
  207-PF TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN Christian Augsberger Received Received
  210-PF CLINICAL ASPECTS AND DIFFERENTIAL SPLICING IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SRSF2, U2AF1 AND SF3B1 MUTATIONS Stefanos Bamopoulos Received Received
  211-PF MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL Reinaldo Dal Bello Received Received
  212-PF NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS Nicholas Short Received Received
  216-PF ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL Bruno Paiva Received Received
  221-PF MUTATIONAL PROFILE BY NGS COMBINED WITH EX VIVO DRUG SENSITIVITY PROFILE IMPROVE PREDICTION OF AML PATIENT OUTCOME Esther Onecha Received Received
  224-PF NOVEL ICMT INHIBITOR AS POTENTIAL TREATMENT OF RAS-DRIVEN ACUTE MYELOID LEUKEMIA Miguel Gallardo Received Received
  226-PF AUTOMATIC SEPARATION OF ABERRANT CELL CLUSTERS IN STANDARDIZED FLOW CYTOMETRY EXPERIMENTS PROVIDES A HIGHLY REPRODUCIBLE STRATEGY FOR MONITORING MINIMAL RESIDUAL DISEASE IN ACUTE MYELOBLASTIC LEUKEMIA VANESA DIAZ Received Received
  228-PF DIAGNOSTIC VALUE OF PU.1 LOCALIZATION IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 Giulia Pianigiani Received Received
  229-PF CLUSTER ANALYSIS IDENTIFIES A SPECIFIC IMMUNOPHENOTYPIC PROFILE ASSOCIATED WITH HIGH RISK OF PRIMARY INDUCTION FAILURE AND SHORTER OVERALL AND DISEASE-FREE SURVIVAL IN NPM1-MUTATED AML piccini matteo Received Received
  235-PF COMPREHENSIVE GENETIC TEST TO DETECT ALL GENE FUSIONS IN HEMATOLOGICAL MALIGNANCIES? Eva van den Berg-de Ruiter Received Received
  243-PF AN MLL-AF9 ZEBRAFISH LEUKAEMIA MODEL Maryam Saberi Received Received
  250-PF HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA Pedro Aguilar-Garrido Received Received
  253-PF SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS Nicholas Howard Received Received
  255-PF INCIDENCE AND RISK FACTORS FOR EARLY DEATH AMONG 2421 APL PATIENTS: THE PETHEMA REGISTRY EXPERIENCE Marta Sobas Received Received
  257-PF GEMTUZUMAB OZOGAMICIN COMBINED WITH CYTARABINE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN FIRST RELAPSE Aude-Marie Fourmont Received Received
  258-PF REAL-WORLD DATA ON DOSE-RELATED EFFECT OF ARSENIC TRIOXIDE IN THE RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA Huaiyu Wang Received Received
  259-PF THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL-INHIBITOR AND LOW-DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY Zoe Roberts Received Received
  264-PF TREATMENT INTENSIFICATION WITH FLAG-IDA MAY IMPROVE DISEASE CONTROL IN YOUNGER PATIENTS WITH SECONDARY AML WHICH MANIFESTS ITSELF WITH LONGER FOLLOW-UP: LONG-TERM ANALYSIS OF THE MRC AML15 TRIAL Robert Hills Received Received
  266-PF COMBINING FLOW CYTOMETRY-BASED LEUKEMIC CELL ENRICHMENT AND MUTATIONAL ANALYSIS FOR DETECTION OF RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA: A PILOT STUDY Albert Woelfler Received Received
  267-PF RISK ASSESSMENT OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH ACUTE LEUKEMIA AND CONCOMITANT ISCHEMIC HEART DISEASE Tetiana Lymanets Received Received
  268-PF DECIPHERING THE ABERRANT IMMUNE MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA DEVELOPMENT AND ITS ROLE IN CHEMOTHERAPY RESPONSE AND RELAPSE Heng Mei Received Received
  270-PF IS ACUTE MYELOBLASTIC LEUKEMIA IN CHILDREN UNDER TWO YEARS OF AGE A SPECIFIC ENTITY? A REPORT FROM THE FRENCH ELAM02 STUDY GROUP. Sophie Blais Received Received
  271-PF USING NEXT-GENERATION SEQUENCING TO PREDICT RESPONSE TO SALVAGE CHEMOTHERAPY WITH HIGH DOSE CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS Jonathan Canaani Received Received
  282-PF THE EFFECT OF MODERN THERAPEUTICS IN ADULT ACUTE MYELOID LEUKEMIA (AML): POPULATION-BASED ANALYSIS OF LONG-TERM OUTCOMES FROM THE MANITOBA CANCER REGISTRY Matthew Seftel Received Received
  283-PF A RETROSPECTIVE STUDY OF MYELOID LEUKAEMIA IN CHILDREN WITH DOWN SYNDROME IN IRELAND Gavin Dowling Received Received
  285-PF ZELLA-101: PHASE 1 STUDY OF ALVOCIDIB FOLLOWED BY 73 INDUCTION IN NEWLY DIAGNOSED AML PATIENTS Stephen Anthony Received Received
  286-PF EARLY ADMISSION IN INTENSIVE CARE UNIT IS ASSOCIATED WITH LOWER MORBIDITY AND MORTALITY IN ACUTE MYELOID LEUKEMIA WITH HYPERLEUKOCYTOSIS: A RETROSPECTIVE ANALYSIS. Nathan Mottal Received Received
  289-PF SOCIOECONOMIC CONSEQUENCES AND OVERALL COSTS PER PATIENT WITH ACUTE MYELOID LEUKAEMIA (AML) IN SWEDEN A POPULATION-BASED STUDY USING MULTIPLE NATIONAL REGISTRIES Simona Vertuani Received Received
  290-PF INCIDENCE AND PROGNOSTIC IMPACT OF A BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM-LIKE PHENOTYPE IN AML PATIENTS. Fabio Guolo Received Received
  295-PF POPULATION-BASED STUDY ON DIFFERENT REGIMENS OF R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA IN THE NETHERLANDS SUPPORTS THE USE OF 6 CYCLES OF R-CHOP21 Djamila Issa Received Received
  301-PF REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL Yasuhiko Miyata Received Received
  302-PF CENTRAL NERVOUS SYSTEM RELAPSE IN DIFFUSE LARGE B CELL LYMPHOMA: RISK FACTORS AND ROLE OF INTRATHECAL PROPHYLAXIS. Eleonora Alma Received Received
  304-PF Osteoporosis And Low-energy Fractures After Treatment For Lymphoma With Corticosteroid-containing Immunochemotherapy: A Danish Nationwide Cohort Study Joachim Bch Received Received
  306-PF A PHASE 2 STUDY OF OFATUMUMAB IN COMBINATION WITH HYPER-CVAD/MA IN PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA Eva Hortas Received Received
  311-PF ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY Fatemeh Majidi Received Received
  315-PF CLINICAL VALUE OF DIFFUSION-WEIGHTED WHOLE-BODY IMAGING WITH BACKGROUND BODY SIGNAL SUPPRESSION IN NEWLY DIAGNOSED LYMPHOMA PATIENTS Eva Hortas Received Received
  316-PF THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH AGGRESSIVE LARGE CELL LYMPHOMA AND DIABETES MELLITUS Oren Pasvolsky Received Received
  325-PF REAL - LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T-CELL LYMPHOMA - A MULTI-CENTER NATIONAL OBSERVATIONAL STUDY shai shimony Received Received
  332-PF THE EFFECT OF ANTITHROMBOTIC STEWARDSHIP ON THE EFFICACY AND SAFETY OF ANTITHROMBOTIC THERAPY DURING AND AFTER HOSPITALIZATION IN TWO DUTCH HOSPITALS Albert Dreijer Received Received
  333-PF RISK OF BLEEDING COMPLICATIONS AND ATRIAL FIBRILLATION ASSOCIATED WITH IBRUTINIB TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS Luca Pellegrini Received Received
  334-PF EPIDURAL/SPINAL ANESTHESIA IN PREGNANT JEWISH ASHKENAZI WOMEN HETEROZYGOTES FOR FACTOR XI DEFICIENCY, A SINGLE CENTER PROSPECTIVE STUDY Adi Shacham Abulafia Received Received
  337-PF ALRN-6924, A DUAL INHIBITOR OF MDMX AND MDM2 THAT CAUSES MINIMAL THROMBOCYTOPENIA IN PATIENTS, DISRUPTS DIFFERENT STAGES OF THROMBOPOIESIS COMPARED TO MDM2-ONLY INHIBITION Allen Annis Received Received
  338-PF DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A Wei Wang Received Received
  340-PF PATIENTS WITH HIGHER BODY MASS INDEX TREATED WITH DIRECT / NON VITAMIN K DEPENDENT ANTICOAGULANTS (DOAC / NOAC) EXPERIENCE WORSE CLINICAL OUTCOMES Marko Lucijanic Received Received
  344-PF HIGH FREQUENCY ASXL1 MUTATIONS AND MULTIPLE SUBCLONAL PIGA MUTATIONS ARE OBSERVED IN CELLULAR AND CELL-FREE DNA IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA Georgie Ryland Received Received
  346-PF Single cell transcriptome analysis reveals an essential role for gata2b in zebrafish hematopoietic lineage decisions Emanuele Gioacchino Received Received
  357-PF A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING Claudia Perez Received Received
  359-PF TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT Luciana Cafforio Received Received
  365-PF PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH BORDERLINE PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Ilaria Del Giudice Received Received
  368-PF DYSREGULATION OF BACH2 AND FOXP1 GENES IN T AND B CELLS IS MORE PRONOUNCED IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGED-MATCHED HEALTHY DONORS WITH AN IMPACT ON SURVIVAL DOMINIQUE BRON Received Received
  370-PF SIGNAL-OMICS ANALYSIS OF THE IMPACT OF THERAPY ON BCR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKAEMIA. Adam Linley Received Received
  373-PF IMPACT OF ATM ALTERATIONS ON CHRONIC LYMPHOCYTIC LEUKEMIA IN GENERAL PRACTICE IN THE AREA OF NEXT GENERATION SEQUENCING Michel Ganard Received Received
  376-PF DIFFERENTIAL GENOMIC AND TRANSCRIPTOMIC EVENTS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA Jenny Klintman Received Received
  379-PF PREVALENCE AND INCIDENCE OF CARDIOVASCULAR DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A NATION-WIDE POPULATION-BASED STUDY. Karin Larsson Received Received
  380-PF SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICOBIOLOGICAL FEATURES AND PROGNOSTIC VALUE Michail Iskas Received Received
  382-PF PROGNOSTIC MODELS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN EXEMPLAR SYSTEMATIC COCHRANE REVIEW AND META-ANALYSIS (PRELIMINARY RESULTS) Nina Kreuzberger Received Received
  388-PF HAT-PCR IS MORE SENSITIVE THAN FLOW FOR QUANTIFYING MRD IN CHRONIC LYMPHOCYTIC LEUKEMIA Alexander Morley Received Received
  390-PF FIRST-LINE TREATMENT WITH LENALIDOMIDE DOES IMPROVE OUTCOME IN ELDERLY/UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS Julia Driessen Received Received
  391-PF INFLUENCE OF ATORVASTATIN THERAPY ON GALECTIN-3, VE-CADHERIN, AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Borys Samura Received Received
  392-PF MONOCLONAL GAMMOPATHY AND HYPOGAMMAGLOBULINEMIA AS INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE. Andrea Corbingi Received Received
  393-PF A RANDOMISED JOINT AUSTRALASIAN (ALLG) AND FRENCH (FILO) STUDY OF LENALIDOMIDE CONSOLIDATION IN PATIENTS WITH RESIDUAL CLL AFTER FRONT-LINE TREATMENT WITH FC/FCR (THE CLL6 TRIAL) David Gottlieb Received Received
  402-PF PECULIARITIES OF THE EXPRESSION OF KI-67 AND CD34 HEMOPOIETIC PRECURSOR CELLS IN PB AND BM OF CML PATIENTS WITH THE DIFFERENT RESPONSES TO IMATINIB AND NILOTINIB THERAPY Tetiana Perekhrestenko Received Received
  410-PF DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL Dennis Kim Received Received
  419-PF ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE ,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS). LUIS FELIPE CASADO MONTERO Received Received
  420-PF RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON PRO-ATHEROTHROMBOTIC EFFECT INDUCED BY TYROSINE-KINASE INHIBITORS FOR FIRST-LINE TREATMENT OF CML PTS (KIARO TRIAL) Anna Sicuranza Received Received
  422-PF THE LONG-TERM TREATMENT RESULTS ACCORDING TO THE MULTICENTER EUTOS ELN POPULATION-BASED STUDY (EUTOS-PBS) IN RUSSIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA Olga Lazareva Received Received
  423-PF SAFETY OF IMATINIB AND ITS GENERICS IN CHRONIC MYELOID LEUKEMIA: A SUBANALYSIS OF POLISH IMATINIB GENERICS REGISTRY AFTER THREE YEARS OF OBSERVATION Joanna W&261;c&322;aw Received Received
  427-PF FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: INITIAL RESULTS OF THE OPEN-LABEL EXTENSION PERIOD OF THE SOAR PHASE 2 STUDY Leslie Todd Received Received
  432-PF EPIDEMIOLOGICAL SHIFT OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) MUTATIONS IN NORTHERN ITALY DURING THE LAST 15 YEARS Giovanna Graziadei Received Received
  433-PF SOLUBLE MANNOSE RECEPTOR IS A POTENTIAL NEW BIOMARKER FOR PLASMA CELL DYSCRASIAS AND OTHER SKELETAL COMPLICATIONS IN GAUCHER DISEASE Brendan Beaton Received Received
  434-PF GLUCOPHOSPHATE ISOMERASE DEFICIENCY IDENTIFIED BY NEXT-GENERATION SEQUENCING Sona Vora Received Received
  435-PF A FLEXIBLE THERAPEUTIC STRATEGY FOR LEUKEMIA USING EX-VIVO EXPANDED T CELLS COMBINED WITH BISPECIFIC ANTIBODIES Josee Golay Received Received
  436-PF GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY Chiara F Magnani Received Received
  437-PF PLATINUM TALEN-MEDIATED NON-VIRAL T CELL RECEPTOR GENE KNOCK-IN FACILITATES UNIVERSAL T CELL GENOME EDITING FOR MANUFACTURING OF THERAPEUTIC IMMUNE CELLS Tatsuo Ichinohe Received Received
  443-PF ADOPTIVE IMMUNOTHERAPY OF INVASIVE ASPERGILLOSIS BY T CELLS VACCINES AGAINST ASPERGILLOSIS IN MOUSE MODEL haizhou xing Received Received
  444-PF IDENTIFICATION OF T-CELL RECEPTORS FROM THE ALLOGENEIC-HLA REPERTOIRE SPECIFIC FOR MELANOMA-ASSOCIATED ANTIGENS Marije de Rooij Received Received
  445-PF INHIBITION OF ACUTE LYMPHOBLASTIC AND MYELOID LEUKEMIAS BY NOVEL CHIMERIC MOUSE-HUMAN MONOCLONAL ANTIBODIES AGAINST ANTIGEN PRAME Andrey Misyurin Received Received
  453-PF TRANSCRIPTOME-PROTEOME CORRELATION IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS Fabienne Meier-Abt Received Received
  456-PF BETA-CATENIN/TCF SIGNALING PATHWAY PROMOTES GRANULOCYTIC DIFFERENTIATION OF HEMATOPOIETIC PROGENITORS BY FACILITATING IL-1 RECEPTOR SIGNALING Petr Danek Received Received
  459-PF ANGELICA SINENSIS POLYSACCHARIDE MAINTAINS THE FUNCTION OF HEMATOPOIETIC STEM CELLS BY REGULATING THE TREG/TH17 RATIO AND THEREBY INDUCES ANTI-MITOCHONDRIAL APOPTOSIS IN APLASTIC ANEMIA xing cui Received Received
  464-PF DEFERASIROX DRIVES ROS-MEDIATED DIFFERENTIATION AND INDUCES INTERFERON-STIMULATED GENES EXPRESSION IN HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS AND IN LEUKEMIA CELLS Tiziana Tataranni Received Received
  467-PF NEW MOLECULES INSPIRED ON MICROBIOTA METABOLITES TARGETING ACUTE MYELOID LEUKEMIA CELLS Sergio Algar Received Received
  469-PF TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: UPDATED FOLLOW-UP EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY Luidi Yang Received Received
  470-PF FIVE-YEAR SURVIVAL AND DURABILITY RESULTS OF THE BEGEV REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA Francesca Ricci Received Received
  471-PF DEPRESSION AND ANXIETY IN HODGKIN LYMPHOMA SURVIVORS: A DANISH NATIONWIDE COHORT STUDY OF 896 PATIENTS Andreas vlisen Received Received
  473-PF PEDIATRIC HODGKIN LYMPHOMA: DISPARITIES IN SURVIVAL BY RACE Karishma Khullar Received Received
  476-PF SALVAGE OPTIONS FOR HD PATIENTS FAILING INITIAL ABVD TREATMENT Oliver Karanfilski Received Received
  485-PF PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB Jorge Castillo Received Received
  489-PF BR VS RCHOP AS INITIAL TREATMENT FOR ADVANCED STAGE FOLLICULAR LYMPHOMA: A MATCHED-PAIR ANALYSIS PAOLO STRATI Received Received
  490-PF PRESENCE OF BRAFV600E MUTATION IN CHILDHOOD LCH CORRELATES WITH MULTISYSTEM DISEASE AND A POOR SURVIVAL PRATEEK BHATIA Received Received
  491-PF RITUXIMAB is an effective therapy for Cold Agglutinin Disease but need to be used cautiously Pierre Daufresne Received Received
  492-PF RESPONSE AND SURVIVAL OUTCOMES OF WALDENSTROM MACROGLOBULINEMIA PATIENTS ON IBRUTINIB THERAPY ON AND OFF CLINICAL TRIAL Jorge Castillo Received Received
  493-PF TP53 STATUS IN MANTLE CELL LYMPHOMA (MCL) - A 10 YEAR SINGLE CENTER EXPERIENCE Ezzat Elhassadi Received Received
  495-PF WHIMSICAL (WALDENSTRMS MACROGLOBULINEMIA STUDY INVOLVING CART-WHEEL): A GLOBAL PATIENT-DERIVED DATA REGISTRY MAPPING TREATMENT AND QUALITY OF LIFE DATA Ibrahim Tohidi-Esfahani Received Received
  500-PF A NEW FTL GENE MUTATION RESPONSIBLE FOR HYPOFERRITINEMIA WITHOUT IRON DEFICIENCY Séverine Cunat Received Received
  501-PF HOMOZYGOUS I281T MUTATION IN HJV CAUSING INDOLENT JUVENILE HEMOCHROMATOSIS WITH A MIDDLE TO LATE ONSET Akiyoshi Takmai Received Received
  504-PF LONG-TERM SEQUENTIAL DEFERIPRONE AND DEFERASIROX THERAPY INTRANSFUSION-DEPENDENT THALASSEMIA PATIENTS: A PROSPECTIVE CLINICAL TRIAL Angela Vitrano Received Received
  507-PF THE HEPCIDIN-ERYTHROFERRONE AXIS AND ITS RELATIONSHIP WITH ERYTHROPOIESIS IN DIFFERENT TYPES OF ANEMIA Rafael Del Orbe Barreto Received Received
  510-PF A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA Maria Carmela Vegliante Received Received
  516-PF ESTROGEN BETA RECEPTOR: A NEW TARGET FOR DIFFUSE LARGE B-CELL LYMPHOMA. Myra Langendonk Received Received
  520-PF C-REL NF-KAPPA B SUBUNIT ACTIVITY REFINES A DISTINCT GERMINAL CENTER DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUP WITH FAVORABLE OUTCOME Jean Feuillard Received Received
  521-PF CHOP TREATMENT ENHANCES DEPENDENCY ON BCL-2, MCL-1 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA Mathilde de Jong Received Received
  526-PF STRUCTURAL AND FUNCTIONAL VARIABILITY OF THE TUMOR B-CELL RECEPTOR INDICATES A ROLE FOR ENVIRONMENTAL INFLUENCES ON BEHAVIOR OF MANTLE CELL LYMPHOMAS David Dutton Received Received
  527-PF PROTEIN KINASE CK1 ALPHA INACTIVATION CAUSES MANTLE CELL LYMPHOMA GROWTH ARREST AND SYNERGISTICALLY ENHANCES IBRUTINIB CYTOTOXICITY Francesco Piazza Received Received
  528-PF INTEGRATING DETECTION OF COPY NEUTRAL CHROMOSOMAL LOSSES IN A CLINICAL SETTING IN LEUKEMIA AND LYMPHOMA BY MEANS OF ALLELIC IMBALANCE AND READ DEPTH RATIO COMPARISON Marcus Hansen Received Received
  531-PF TRANSFORMING ACTIVITIES OF THE NUP98-KMT2A FUSION GENE ASSOCIATED WITH MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA James Fisher Received Received
  532-PF INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. Suguru Morimoto Received Received
  533-PF MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS Marta Martín Izquierdo Received Received
  534-PF COPY NUMBER VARIATIONS AND UNIPARENTAL DISOMY PREDICT POOR SURVIVAL IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE AND ARE ASSOCIATED WITH MACROCYTOSIS Stine Ulrik Mikkelsen Received Received
  535-PF CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS. GABRIELE TODISCO Received Received
  539-PF MIR-223 IS SUPPRESSED IN EXOSOMES OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND MAY BE A MARKER OF RESIDUAL GRANULOCYTIC-MONOCYTIC DIFFERENTIATION Bruno Benites Received Received
  543-PF PROMOTER METHYLATION OF TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA Naoki MORI Received Received
  545-PF EASIX FOR PREDICTION OF SURVIVAL IN LOWER RISK MYELODYSPLASTIC SYNDROMES Almuth Maria Anni Merz Received Received
  547-PF FACTORS ASSOCIATED WITH THE NEED FOR TRANSFUSIONS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME (MDS). DATA FROM THE REGULAR CARE MDS-REGISTRY IN GERMANY H.T. Steinmetz Received Received
  550-PF AZACITIDINE (VIDAZA) IN PEDIATRIC PATIENTS WITH RELAPSED ADVANCED MDS: RESULTS OF A PHASE I/II STUDY BY THE ITCC CONSORTIUM AND THE EWOG-MDS GROUP: STUDY ITCC-015 Natasha van Eijkelenburg Received Received
  554-PF A GENOME-WIDE CRISPR SCREEN IDENTIFIES TOP2B AS AN ACQUIRED DRUGGABLE VULNERABILITY IN THE CONTEXT OF IMID RESISTANCE Matteo Costacurta Received Received
  561-PF DUAL-TARGETING OF PROMOTER AND ENHANCER DRIVEN PROCESSES SUPPRESSES MYELOMA CELL GROWTH AND VIABILITY VIA PERTURBATION OF THE MYELOMA PROLIFERATIVE PROGRAM. Mariateresa Fulciniti Received Received
  563-PF MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) Nouf Alrasheed Received Received
  565-PF MMBMSCS INDUCE IMMUNOSENESCENT NAVE CD4 T-CELLS THROUGH THE NOVEL INTERCELLULAR COMMUNICATION TUNNELING NANOTUBES Yadan Wang Received Received
  566-PF INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY Alejandra Ortiz-Ruiz Received Received
  572-PF ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE- AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA Takuto Tachita Received Received
  573-PF SINGLE CELL RNA-SEQ REVEALED A RARE ITGA2 EXPRESSING CELL SUBPOPULATION WITH DISTINCT CANCER STEM CELL MARKER SIGNATURE IN MULTIPLE MYELOMA Margaret Ng Received Received
  579-PF TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA. Paola Omedè Received Received
  582-PF PARTICIPATION OF IMMUNE RESPONSE GENES POLYMORPHISM IN THE OCCURRENCE OF SOLID TUMORS IN PATIENTS WITH MULTIPLE MYELOMA Elena Nazarova Received Received
  586-PF SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY Alessandra Larocca Received Received
  606-PF ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA Amani Erra Received Received
  607-PF MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012-03). Arthur Bobin Received Received
  611-PF MULTIPLE DRUG COMBINATIONS FOR FIRST-LINE TREATMENT IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Vanessa Piechotta Received Received
  615-PF IMPACT OF PATIENTS CHARACTERISTICS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE CHARISMMA STUDY MARTA GRANDE Received Received
  620-PF COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL Femke de Snoo Received Received
  621-PF REAL WORLD EXPERIENCE IN THE MANAGEMENT OF WALDENSTRMS MACROGLOBULINAEMIA FROM ANALYSIS OF THE RORY MORRISON REGISTRY Joshua Bomsztyk Received Received
  627-PF SERUM CEREBLON LEVELS PREDICT FIVE- YEAR POST LEALIDOMIDE/DEXAMETHASONE (RD) SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS AND CORRELATE WITH DISEASE CHARACTERISTICS. Annita Ioanna Gkioka Received Received
  630-PF MINIMAL RESIDUAL DISEASE MONITORING AND DEPTH OF RESPONSE IN MULTIPLE MYELOMA Eva Hortas Received Received
  633-PF PROGNOSTIC VALUE OF KIDNEY BIOPSY INTERSTITIAL FIBROSIS IN REVERSIBILITY OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY DUE TO MYELOMA CAST NEPHROPATHY Evgeniya Kazarina Received Received
  634-PF OUTCOMES OF SALVAGE WITH INFUSIONAL REGIMENS DT-PACE/ESHAP FOR REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MM) Louise Ainley Received Received
  635-PF SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS Hiroki Kobayashi Received Received
  636-PF NATURAL KILLER CELL ALLOREACTIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS Catharina Van Elssen Received Received
  638-PF Real world data examining the use of Ixazomib, Lenalidomide and Dexamethasone (ILD) and Lenalidomide and Dexamethasone (LD) chemotherapy in Multiple Myeloma Keonwoo Yi Received Received
  642-PF REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS A SINGLE CENTRE EXPERIENCE Amanda Jurgensen-Rauch Received Received
  650-PF AGE DOES NOT CONFER DIFFERENT FEATURES AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED ACTIVE MULTIPLE MYELOMA YOUNGER THAN 66 YEARS OF AGE TREATED IN A RECENT PERIOD. ELOISA RIVA Received Received
  656-PF EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS kristian boasman Received Received
  657-PF USE OF A NGS MYELOID PANEL TO FIND CLONALITY IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA. IDENTIFICATION OF NEW MUTATIONS IN DRIVER GENES Gonzalo Carreno Received Received
  659-PF MYELOMONOCYTIC SKEWING IN VITRO DISCRIMINATES SUBGROUPS OF PATIENTS WITH MYELOFIBROSIS WITH A DIFFERENT PHENOTYPE, A DIFFERENT GENOTYPE AND DIFFERENT PROGNOSIS Temeida Graf Received Received
  660-PF TRANSCRIPTIONAL PROFILES OF PRIMARY CULTURES OF ERYTHROID AND MEGAKARYOCYTIC CELLS IN ESSENTIAL THROMBOCYTHEMIA UNCOVER A HIGH DEGREE OF GENE DEREGULATION IN THE MEGAKARYOCYTIC LINEAGE. Petros Papadopoulos Received Received
  661-PF MOLECULAR PROFILING REVEALS HIGHLY DEREGULATED INSULIN GROWTH FACTOR BINDING PROTEINS IN PATIENTS WITH MYELOFIBROSIS AND RELATED NEOPLASMS Vibe Skov Received Received
  664-PF 46/1 HAPLOTYPE IS ASSOCIATED WITH A HIGHER MONOCYTE/LYMPHOCYTE RATIO IN HEALTHY INDIVIDUALS Gonzalo Carreno Received Received
  665-PF SERUM FERRITIN LEVELS ARE INCREASED IN IDIOPATHIC ERYTHROCYTOSIS BUT REDUCED IN POLYCYTHEMIA VERA Giacomo Biagetti Received Received
  669-PF RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS Chiara Cavalloni Received Received
  670-PF MOLECULAR CLASSIFICATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA WHO DEVELOP RESISTANCE OR INTOLERANCE TO HYDROXYUREA Álvaro Díaz Received Received
  673-PF PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML) PRITHVIRAJ BOSE Received Received
  674-PF OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS Francesca Palandri Received Received
  675-PF JAK2V617F AND MPL MUTATIONS ARE ASSOCIATED WITH WORSENED SYMPTOM BURDEN THAN CALR IN THE MYELOPROLIFERATIVE NEOPLASMS: FINDINGS FROM THE MYMPN PATIENT REGISTRY Robyn Scherber Received Received
  676-PF BODY MASS INDEX AND TOTAL SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASMS DISCOVERY OF A U-SHAPED ASSOCIATION Robyn Scherber Received Received
  682-PF MULTICENTER RETROSPECTIVE STUDY EVALUATING FIBROSIS RISK IN PATIENTS WITH ET DEPENDING ON THE TREATMENT SCENARIO Marta Sobas Received Received
  683-PF ARTERIAL THROMBOSIS IN YOUNG PV PATIENTS Giulia Bogoni Received Received
  684-PF ANAGRELIDE MODULATES PROPLATELET FORMATION RESULTING IN DECREASED NUMBER AND INCREASED SIZE OF PLATELETS Naohiro Miyashita Received Received
  686-PF HEALTHCARE RESOURCE IMPLICATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS Ximena Cabrera Castellano Received Received
  687-PF RISK OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ACCORDING TO THE JAK2 V617F ALLELE BURDEN Sung Hwa Bae Received Received
  689-PF SAFETY AND EFFICACY OF ROMIPLOSTIM IN OVER 200 CHILDREN WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN AN INTEGRATED DATABASE OF 5 CLINICAL TRIALS Jonathan Latham Received Received
  695-PF ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP Elisa Lucchini Received Received
  703-PF LONG-TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM Leslie Todd Received Received
  707-PF INCIDENCE AND OUTCOMES OF REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN; A SINGLE INSTITUTION EXPERIENCE Masataka Ito Received Received
  716-PF CLINICAL IMPACT OF PROGNOSTIC NUTRITIONAL INDEX IN DIFFUSE LARGE B CELL LYMPHOMA Gyeong-Won Lee Received Received
  717-PF QUALITY OF LIFE (QOL), PERSPECTIVES ON TREATMENT AND IMPORTANT OUTCOMES FOR MULTIPLE MYELOMA (MM) PATIENTS AND THEIR CARERS: A MIXED METHODS EVIDENCE SYNTHESIS Keith Stubbs Received Received
  718-PF THE ECONOMIC AND HUMANISTIC BURDEN OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PEDIATRIC PATIENTS: A SYSTEMATIC LITERATURE REVIEW (SLR) Anna Forsythe Received Received
  727-PF DOES QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS DIFFER BETWEEN NATIONALITIES? A EUROPEAN MULTINATIONAL STUDY Ayesha Sajjad Received Received
  730-PF CHRONIC RENAL FAILURE IN CHILDHOOD CANCER: AN INSIGHT FROM KIDS INPATIENT DATABASE Eman Elsabbagh Received Received
  732-PF AN INDEPENDENT OBSERVATIONAL STUDY OF REAL LIFE COSTS OF CARE TO MYELOMA PATIENTS IN THE ERA OF NOVEL THERAPIES Jane Thompson Received Received
  742-PF CEREBRAL OXYGEN METABOLISM MEASUREMENTS WITH MRI IN ADULTS WITH SICKLE CELL DISEASE Lena Vaclavu Received Received
  743-PF PENICILLIN PROPHYLAXIS AND PNEUMOCOCCAL VACCINE USE IN ADULT SICKLE CELL PATIENTS: A RETROSPECTIVE ANALYSIS OF CLINICAL PRACTICE AND OUTCOMES IN OXFORD, UK Ayesha Ejaz Received Received
  745-PF HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANT FOR POEMS SYNDROME: EFFECTIVE, BUT HOW TO OPTIMISE? Oliver Tomkins Received Received
  753-PF IMPACT OF ANTI-THYMOCYTE GLOBULIN DOSES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELOID NEOPLASM JUN YEB NAM Received Received
  756-PF DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION Kaori Uchino Received Received
  757-PF REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE. Nancy Rodriguez Received Received
  759-PF ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON. Andrea Corbingi Received Received
  763-PF STEM CELL TRANSPLANTATION FOR MANTLE-CELL LYMPHOMA - A SINGLE CENTRE EXPERIENCE (2010-2018) Telma Nascimento Received Received
  766-PF T CELL EXHAUSTION PROFILE (CD4/CD28/PER/GRA CD8/CD28/PER/GRA) IN STEMCELL TRANSPLANTATION, CMV RE ACTIVATIONS AND RESPIRATORY VIRUS INFECTION.CELLULAR DYNAMICS IN THE FIRST 100 DAYS POST SCT Miguel Villanueva Received Received
  770-PF OUTCOMES FOR MELPHALAN-VELCADE BASED AUTOGRAFT IN HIGH RISK MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTRE EXPERIENCE David Routledge Received Received
  775-PF MONOSOMY 7 ALONE OR WITH OTHER CHROMOSOMAL ABNORMALITIES SIGNIFICANTLY AFFECT SURVIVAL OF SECONDARY AML PATIENTS TREATED WITH ALLOGENEIC- SCT Mona Hassanein Received Received
  787-PF THE EFFICACY OF ALENDRONATE FOR THE TREATMENT OF THALASSEMIA-ASSOCIATED OSTEOPOROSIS: A RANDOMIZED CONTROLLED TRIAL Pokpong Piriyakhuntorn Received Received
  788-PF DATA FROM THE FRENCH REGISTRY FOR BETA-THALASSEMIA PATIENTS Badens Catherine Received Received
  789-PF 8-YEARS OVERALL AND EVENT FREE SURVIVAL IS SUBOPTIMAL IN A LARGE GROUP OF TRANSFUSION-DEPENDENT THALASSEMIC PATIENTS antonis kattamis Received Received
  791-PF IMPAIRMENT OF GLUTATHIONE SYSTEM AND LIPID PEROXIDATION IN PATIENTS WITH HB H DISEASE ANTONIS KATTAMIS Received Received
  795-PF EXPLORING THE REAL-LIFE CLINICAL VALUE OF LOW DOSE DIRECT ANTICOAGULANTS FOR SECONDARY PREVENTION OF THROMBOEMBOLISM CHARALAMPOS KARTSIOS Received Received
  802-PF ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L Sergio Siragusa Received Received
  803-PF VON WILLEBRAND FACTOR DELAYS LIVER REPAIR AFTER ACETAMINOPHEN-INDUCED ACUTE LIVER INJURY IN MICE. Dafna Groeneveld Received Received
  813-PF PROFILE OF BLOOD DONORS WITH SEROLOGIC TESTS REACTIVE IN HOSPITAL METROPOLITANO IN QUITO- ECUADOR FROM JANUARY 2016 TO DECEMBER 2018. johanna rojas Received Received
  817-PF INTENSIVE PLAN OF THERAPEUTIC PLASMA EXCHANGE IN PATIENT WITH EXTREME HYPERTRLIGLYCERIDEMIA DUE TO L-ASPARAGINASE IN THE CONTEXT OF SMILE PROTOCOL IN T/NK NASAL LYMPHOMA TREATMENT Eduardo Sobejano Received Received
  914-PS CONDITIONAL MEF2C EXPRESSION IN THE MOUSE THYMUS DRIVES DEVELOPMENT OF T/B-BIPHENOTYPIC LYMPHOID LEUKEMIA/LYMPHOMA Kirsten Canté-Barrett Received Received
  918-PS CIRCRNA DEREGULATION IN B-CELL PEDIATRIC ACUTE LEUKEMIA: THE MLL RECOMBINOME AND BEYOND Stefania Bortoluzzi Received Received
  919-PS ROLE OF CHOROID PLEXUS STROMA IN TUMOUR CHEMORESISTANCE: A SANCTUARY FOR LEUKAEMIA CELLS IN THE CENTRAL NERVOUS SYSTEM Lidia Martínez Received Received
  921-PS INACTIVATION OF SH2B3 THROUGH CN-LOH 12Q IS UNIQUELY ASSOCIATED WITH B-CELL PRECURSOR ALL WITH IAMP21 OR OTHER CHROMOSOME 21 GAIN. Paul Sinclair Received Received
  933-PS DISCOVERING PATHWAYS INVOLVED IN RESISTANCE TO INDUCTION THERAPY IN T-ALL TO TREAT REFRACTORY AND RELAPSED DISEASE Melanie Beckett Received Received
  935-PS APPLICABILITY OF DROPLET DIGITAL PCR (DDPCR) FOR MINIMAL RESIDUAL DISEASE MONITORING (MRD) IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA Sabina Chiaretti Received Received
  937-PS RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL Anita Rijneveld Received Received
  938-PS INTENSIVE PAEDIATRIC THERAPY IS AS DELIVERABLE IN ADOLESCENTS AND YOUNG ADULTS AS CHILDREN WITH ALL - PRELIMINARY RESULTS OF THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) ALL06 STUDY Matthew Greenwood Received Received
  941-PS ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT IMPROVES LONG-TERM OUTCOME OF B-ALL PATIENTS WITH HIGH LEUKEMIA BURDEN OR POOR PROGNOSTIC MARKERS Heng Mei Received Received
  942-PS CD19 MUTATION FREQUENCY AFTER BLINATUMOMAB TREATMENT IS LOWER THAN AFTER CAR T-CELLS TREATMENT Michaela Kotrova Received Received
  943-PS SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE Marie Emilie Dourthe Received Received
  952-PS NELARABINE AS SALVAGE THERAPY FOR PEDIATRIC PATIENTS WITH RELAPSED T-ALL luciana vinti Received Received
  956-PS A MULTICENTER, RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA SEUNG SHIN LEE Received Received
  957-PS Initial safety and efficacy of larotrectinib in patients with B lymphoblastic leukaemia:data from an expanded access programme Annabel Ola Received Received
  958-PS IMPROVING THE SAFETY OF CAR-T CELL THERAPY BY CONTROLLING CRS-RELATED COAGULOPATHY Heng Mei Received Received
  963-PS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: DOES MINIMAL RESIDUAL DISEASE BEFORE TRANSPLANTATION MATTER FOR LONG TERM OUTCOME? Irati Ormazabal Velez Received Received
  970-PS ACUTE MYELOID LEUKEMIA CELLS ARE DEPENDENT ON S100A4 FOR GROWTH AND SURVIVAL Bader Alanazi Received Received
  982-PS THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA Dagmar Stoiber Received Received
  984-PS CANNABINOIDS EXERT A POTENT ANTI-LEUKEMIC EFFECT AFFECTING SIGNALING PATHWAYS INVOLVED IN TUMOR CELL METABOLISM. Mayte Medrano Received Received
  991-PS CA-4948, AN IRAK4/FLT3 INHIBITOR, SHOWS ANTILEUKEMIC ACTIVITY IN MOUSE MODELS OF FLT3 WILD-TYPE AND FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) Robert Booher Received Received
  992-PS MSI2 REGULATES BACH1/BRIP1 THUS AFFECTING THE OXIDATIVE STRESS RESPONSE Jessica Hoell Received Received
  995-PS IMPACT OF DNMT3A MUTATIONAL STATUS IN MOLECULAR MEASURABLE RESIDUAL DISEASE CLEARANCE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 Guadalupe Oñate Received Received
  996-PS TCF4 IS IMPORTANT FOR MUTANT RUNX1-MEDIATED CELL IMMORTALIZATION AND PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA Florentien in t Hout Received Received
  1002-PS RHOE, CXCL12 AND CXCR3 MAY IDENTIFY COMPLETE RESPONSES IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH TIPIFARNIB Antonio Gualberto Received Received
  1006-PS INHIBITORS OF HOXA9 LEUKEMOGENIC TRANSCRIPTION FACTOR ARE EFFICIENT ON HUMAN AML CELL MODELS BUT NOT ON NORMAL HUMAN BONE MARROW CD34 HEMATOPOIETIC CELLS Marie-Helene David-Cordonnier Received Received
  1008-PS A NEW NEXT-GENERATION SEQUENCING STRATEGY FOR THE SIMULTANEOUS DETECTION OF GENE MUTATIONS AND COPY NUMBER VARIATIONS IN MYELOID MALIGNANCIES M. Isabel Prieto-Conde Received Received
  1016-PS COMPARATIVE ANALYSES OF LEUKEMIC BLAST PHENOTYPE AND MUTANT/WT EXPRESSION RATIO IN FLT3-ITD ACUTE MYELOID LEUKEMIAS Dan-Sebastian Soare Received Received
  1017-PS MICRO RNA SIGNATURE OF ONCOGENIC MUSASHI RNA BINDING PROTEINS MSI1 AND MSI2 Sujitha Duggimpudi Received Received
  1028-PS ALLG APML5: A COMPARATIVE BIOAVAILABILITY STUDY OF ENCAPSULATED ORAL ARSENIC TRIOXIDE AND INTRAVENOUS ARSENIC TRIOXIDE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY Harry Iland Received Received
  1031-PS DECITABINE VERSUS INTENSIVE CHEMOTHERAPY IN ELDERLY UNTREATED ACUTE MYELOID LEUKEMIA Adolfo de la Fuente Received Received
  1032-PS SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50-75 YEARS A SWEDISH POPULATION-BASED STUDY Gunnar Juliusson Received Received
  1034-PS PHASE I DOSE ESCALATION CLINICAL TRIAL OF H3B-8800, A SPLICING MODULATOR, IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES Huilan Yao Received Received
  1037-PS FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS Iphigenia Koumenis Received Received
  1040-PS DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS Jing Wamg Received Received
  1045-PS INDIRECT NUMBER NEEDED TO TREAT: COMPARATIVE EFFECTIVENESS OF GLASDEGIB LOW-DOSE CYTARABINE VS AZACITIDINE OR DECITABINE IN ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY Anna Forsythe Received Received
  1046-PS FLT3 LIGAND PLASMA LEVELS HAVE NO IMPACT ON OUTCOMES AFTER ALLOTRANSPLANT IN ACUTE LEUKEMIA. Pierre Peterlin Received Received
  1047-PS EFFICACY AND SAFETY EVALUATION OF DIFFERENT DOSES OF ANTHRACYCLINES IN THE INDUCTION THERAPY FOR NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA Xiaohui Hu Received Received
  1050-PS MARKER CHROMOSOME IS A STRONG POOR PROGNOSIS FACTOR AFTER ALLOGENEIC HSCT FOR AML PATIENTS Kyoko Fuse Received Received
  1054-PS INTENSIFIED CONDITIONING WITH FLUDARABINE/MELPHALAN PLUS TOTAL BODY IRRADIATION VERSUS FLUDARABINE/MELPHALAN ALONE FOR ACUTE MYELOID LEUKEMIA Sarah Lindner Received Received
  1056-PS ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH CHROMOSOME 17 ABNORMALITIES AND LONG-TERM OUTCOMES WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION GHULAM REHMAN MOHYUDDIN Received Received
  1057-PS INDUCTION WITH FLUGA SCHEME AND MAINTENANCE WITH DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OF 65 YEARS AND OLDER Sofía Costa Received Received
  1071-PS PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES. Shannon Matheny Received Received
  1074-PS SANDOZ RITUXIMAB FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE PROSPECTIVE NON-INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN-LABEL REFLECT STUDY Jess Fox Received Received
  1077-PS EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP Kitsada Wudhikarn Received Received
  1084-PS AUTOLOGOUS STEM CELL TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA: SIMILAR OUTCOMES AFTER BEAM AND FEAM CONDITIONING REGIMENS Bruno Loureiro Received Received
  1096-PS INTERIM UPDATE FROM A MULTI-CENTER STUDY OF PRALATREXATE IN ASIAN PATIENTS WITH RELAPSED OR REFRACTORY(R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) Bor-Sheng Ko Received Received
  1098-PS ADULT ONSET HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA WITH A NOVEL ADAMTS13 MUTATION Julian Freue Received Received
  1104-PS EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION Elena Egorova Received Received
  1114-PS PATIENTS WITH GAUCHER DISEASE SHOW AN IMMUNE-DYSREGULATION PATTERN SECONDARY TO A DEFECT OF APOPTOSIS Maurizio Miano Received Received
  1119-PS PNH CLONE SIZE BY FLOW CYTOMETRY AND ITS CORRELATION TO PIG GENE MUTATION Dajeong Jeong Received Received
  1120-PS IRON MOBILIZATION IN A REAL LIFE COHORT OF APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG Francesca Cavallaro Received Received
  1121-PS ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA Jennifer Tjon Received Received
  1128-PS FUNGI INFECTION VERSUS IBRUTINIB TREATMENT: ROLE OF NURSE-LIKE CELLS DURING ASPERGILLUS FUMIGATUS INFECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Stefania Fiorcari Received Received
  1130-PS STEM CELL FACTOR IS IMPLICATED IN MICROENVIRONMENTAL INTERACTIONS AND CELLULAR DYNAMICS OF CHRONIC LYMPHOCYTIC LEUKEMIA Stavroula Ntoufa Received Received
  1132-PS INHERITED DNA REPAIR AND CELL CYCLE GENE DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA Jennifer Brown Received Received
  1138-PS TUMOR MUTATIONAL BURDEN ASSESSED BY TARGETED HIGH THROUGHPUT SEQUENCING PREDICTS TREATMENT FREE SURVIVAL IN CLL: RESULTS FROM A BICENTER STUDY Jean Feuillard Received Received
  1141-PS PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT; RESULTS FROM THE HOVON-109 STUDY Fatemeh Saberi Hosnijeh Received Received
  1152-PS THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE Luca Laurenti Received Received
  1153-PS IMPACT OF COMORBIDITIES ON OUTCOMES OF THERAPY WITH IDELALISIB (IDELA), A PHOSPHOINOTISIDE-3 KINASE-DELTA INHIBITOR, IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Max Gordon Received Received
  1155-PS A PHASE I/II STUDY OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Alexey Danilov Received Received
  1171-PS TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB Natalia Estrada Received Received
  1172-PS DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME Gioia Colafigli Received Received
  1175-PS DETECTING BCR-ABL AND SCORING MR: RESULTS FROM A CE-IVD KIT RUN ON NON-IVD PCR INSTRUMENTS: A COMPARISON WITH DATA FROM A EUTOS VALIDATED LAB. Jesper Petersen Received Received
  1177-PS PROGNOSTIC FACTORS FOR MOLECULAR RELAPSE-FREE SURVIVAL AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA BASED ON RUSSIAN MULTICENTER PROSPECTIVE TRIAL (RU-SKI) Oleg Shukhov Received Received
  1179-PS TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS HARBOURING ATYPICAL BCR-ABL1 TRANSCRIPTS MATTEO DRAGANI Received Received
  1180-PS FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) Kiran Naqvi Received Received
  1184-PS ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE Asif Iqbal Received Received
  1193-PS CHARACTERISTICS AND OUTCOMES OF THE TREATMENT PATIENTS WITH T315I MUTATION CML Julia Vlasova Received Received
  1196-PS INNOVATIVE DIAGNOSTIC APPROACH FOR RARE ANEMIA Valeria Rizzuto Received Received
  1197-PS ASSESSING THE EMA BINDING TEST AND OSMOTIC GRADIENT EKTACYTOMETRY IN THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS DEFINED BY THE PRESENCE OF UNDERLYING DIAGNOSTIC MUTATIONS Andreas Glenthoej Received Received
  1203-PS HEREDITARY SPHEROCYTOSIS: SCREENING AND DIAGNOSTIC APPROACH IN A BELGIAN LABORATORY Edith Sepulchre Received Received
  1204-PS SEVERE HEREDITARY HAEMOLYTIC ANAEMIA DUE TO THREE NOVEL SPTA1 MUTATIONS IN TWO COMPOUND HETEROZYGOUS UNRELATED PATIENTS. Juan-Luis Vives-Corrons Received Received
  1209-PS NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS. Elena Maroto Martin Received Received
  1214-PS INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4-1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19 RELAPSED / REFRACTORY MALIGNANCIES Valentín Ortiz-Maldonado Received Received
  1215-PS SAFETY AND TOLERABILITY OF ALLOGENEIC, OFF-THE SHELF PLACENTAL NATURAL KILLER CELLS (PNK 007) IN PHASE 1 MULTIPLE MYELOMA AND ACUTE MYELOID LEUKEMIA STUDIES (NCT02955550 AND NCT02781467) Sharmila Koppisetti Received Received
  1219-PS CAUSES OF NON ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL Jérme PAILLASSA Received Received
  1222-PS IL-6 ASSOCIATED WITH GRADING OF CYTOKINE RELEASE SYNDROME AND MANAGEMENT TIME OF TOCILIZUMAB AFTER CAR-T CELL THERAPY Heng Mei Received Received
  1224-PS DOWNREGULATION OF ENDOTHELIAL GENE MYCT1 IN HUMAN HSCS DURING EX VIVO CULTURE COMPROMISES THEIR FUNCTION Julia Aguade-Gorgorio Received Received
  1228-PS SF3B1 KNOCKDOWN AT EARLY ERYTHROPOIESIS INDUCED CELL APOPTOSIS BY USING A TET-ON LENTIVIRAL VECTOR Yumin Huang Received Received
  1237-PS DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI Rita Mazza Received Received
  1245-PS NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI-CENTER EXPERIENCE IN TURKEY Burhan Ferhanoglu Received Received
  1248-PS COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL Daniele Grimaldi Received Received
  1254-PS CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND-LINE RITUXIMAB-CONTAINING CHEMOTHERAPY Jiajia Liu Received Received
  1255-PS EFFICACY OF R-BAC IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITOR THERAPY Rory McCulloch Received Received
  1258-PS CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS CHRISTINA KALPADAKIS Received Received
  1259-PS LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA Michinori Ogura Received Received
  1266-PS CLINICAL ASPECTS, MORPHOLOGICAL ANALYSIS AND IMMUNOHISTOCHEMICAL CHARACTERISTICS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN DUODENUM BIOPSY: CASES WITH RESTRICT DISEASE VERSUS ADVANCED PRESENTATION. Guilherme Brasil Duffles Amarante Received Received
  1269-PS AUTOIMMUNE NEUTROPENIA OF INFANCY- UNEXPECTED PREVALENCE OF PSEUDOMONAS SKIN INFECTIONS Joanne Yacobovich Received Received
  1270-PS HIGH INCIDENCE OF CYTOMEGALOVIRUS (CMV) REACTIVATION IN HEMATOLOGICAL PATIENTS TREATED WITH BENDAMUSTINE BASED CHEMOTERAPY REGIMENS luca pezzullo Received Received
  1274-PS EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION INADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: ARETROSPECTIVE MONOCENTER STUDY Francesca Bettelli Received Received
  1276-PS EPIDEMIOLOGY AND CLINICAL OUTCOME OF FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS. GABRIELE FACCHIN Received Received
  1284-PS GLOBAL GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF MUCORMYCOSIS: AN INITIATIVE OF THE ECMM IN COOPERATION WITH THE MSG ERC Kerstin Albus Received Received
  1289-PS THE ATYPICAL LYMPHOCYTE COUNT: A NOVEL PREDICTIVE FACTOR FOR SEVERE DENGUE INFECTION Visula Abeysuriya Received Received
  1291-PS THE DEVELOPMENT OF IRON OVERLOAD SYNDROME IN PATIENTS WITH LOW-/INTERMEDIATE RISK MYELODYSPLASTIC SYNDROME Tatiana Babaeva Received Received
  1292-PS LINK BETWEEN IRON AND TRYPTOPHAN METABOLISM OBSERVED IN INDIVIDUALS WITH IRON DEFICIENCY AND ANEMIA Dietmar Enko Received Received
  1300-PS A NURSE LED IRON INFUSION CLINIC IMPROVES PATIENT SAFETY AND REDUCES HEALTH CARE COSTS Laurie Newman Received Received
  1307-PS USE OF T CELL-SPECIFIC RNA IN SITU HYBRIDISATION AS A NOVEL TEST TO DISTINGUISH MALIGNANT (LYMPHOMATOUS) AND BENIGN (INFLAMMATORY) T CELL INFILTRATES Elizabeth Soilleux Received Received
  1315-PS CHANGES IN THE SECRETOME COMPOSITION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA WITHOUT BONE MARROW INVOLVEMENT Nataliya Petinati Received Received
  1317-PS VITAMIN D3 INHIBITS GROWTH OF HODGKIN CELL LINES AND IMPROVES SENSITIVITY TO CHEMOTHERAPY AT PHYSIOLOGICAL DOSES IN VITRO AND IN VIVO. Melita Cirillo Received Received
  1319-PS MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19 SELECTED AND UNSELECTED SAMPLES Daniela Drandi Received Received
  1321-PS INHIBITION OF NOTCH SIGNALING RESTORES SENSITIVITY TO IMMUNOCHEMOTHERAPY IN AN IN VITRO MODEL OF ACQUIRED RESISTANCE TO R-CHOP Giovanni Di Pinto Received Received
  1323-PS HIGH SERUM LEVELS OF IL-2R, IL-6, AND TNF ARE ASSOCIATED WITH HIGHER TUMOR BURDEN AND POORER OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA Pablo MOZAS Received Received
  1325-PS IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA Yue Wei Received Received
  1327-PS RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BM OF PATIENTS WITH MDS AND CMML Veronika Dill Received Received
  1330-PS VARIABILITY IN THE EXTENT OF DEL(5Q) AND ITS CLINICAL IMPLICATION IN MYELODYSPLASTIC SYNDROMES (MDS). Zuzana Zemanova Received Received
  1331-PS MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL Temeida Graf Received Received
  1332-PS RIGOSERTIB MODULATES HEMATOPOIESIS GENE SIGNALING PATHWAYS ALONE OR IN SEQUENCED COMBINATION WITH AZACTIDINE ON MDS CELLS IN VITRO. Lewis R Silverman Received Received
  1333-PS OVEREXPRESSION OF PROTEIN TYROSINE PHOSPHATASE NON-RECEPTOR TYPE1 CAUSES STAT5 DEPHOSPHORYLATION, RESULTING IN SUPPRESSION OF CELL GROWTH SIGNAL IN K562 HUMAN LEUKEMIA CELLS MASAYUKI SHISEKI Received Received
  1339-PS UNSUPERVISED HIERARCHICAL CLUSTERING OF PRE-TREATMENT IMMUNOPHENOTYPIC FEATURES IDENTIFIES MDS PATIENTS AT HIGH RISK OF DISEASE PROGRESSION AFTER ALLOGENEIC TRANSPLANTATION Madlen Jentzsch Received Received
  1341-PS CLINICAL SIGNIFICANCE OF KIR GENOTYPE IN JAPANESE PATIENTS WITH MYELODYSPLASTIC SYNDROME Norina Tanaka Received Received
  1342-PS PREDICTING SURVIVAL AND TRANSFORMATION IN YOUNG AND MIDDLE-AGED PATIENTS WITH MYELODYSPLASTIC SYNDROME Natalia Klimkovich Received Received
  1345-PS CIRCULATING TUMOR DNA AS A LIQUID BIOPSY IN SMOLDERING MULTIPLE MYELOMA TO IDENTIFY BIOMARKERS OF PROGRESSION Martina Manzoni Received Received
  1350-PS STRONG PRE-CLINICAL RATIONAL FOR THE USE OF MCL1/BCL2 BH3 MIMETIC COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 MIMETIC ALONE Carolane Seiller Received Received
  1351-PS CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL. Ana Jimenez Ubieto Received Received
  1354-PS MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION Saeko Ota Received Received
  1360-PS LONG NON-CODING RNA NEAT1 TARGETING TRIGGERS ANTI-TUMOR ACTIVITY AND RESULTS IN CHEMO-SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS Elisa Taiana Received Received
  1366-PS TISSUE ENGINEERING OF AN ORTHOTOPIC HUMANIZED BONE-ORGAN AS A PLATFORM FOR PRECLINICAL MULTIPLE MYELOMA RESEARCH Alvaro Sanchez Received Received
  1367-PS COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN Takashi Kanamori Received Received
  1368-PS IGH AND IGK REARRANGEMENT AND IGH SOMATIC HYPERMUTATION ANALYSIS USING NEXT-GENERATION SEQUENCING FOR THE DETECTION OF CLONALITY IN HIGH-RISK KOREAN MULTIPLE MYELOMA PATIENTS Young Kyung Lee Received Received
  1371-PS ELOTUZUMAB IN COMBINATION WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 2 MMRC TRIAL Donna Stefanoni Received Received
  1383-PS A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01-16) Anna Kalff Received Received
  1386-PS CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA Frits van Rhee Received Received
  1397-PS OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA Brett Grieb Received Received
  1398-PS RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT Julio Davila Received Received
  1402-PS OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM. Camila Peña Received Received
  1403-PS IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) IN EUROPE: A HETEROGENEOUS DISEASE TREATED WITH A VARIETY OF AGENTS Sheila Pierson Received Received
  1406-PS WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA Cecile Gruchet Received Received
  1408-PS PROGNOSTIC SIGNIFICANCE OF CD56 EXPRESSION ON BONE MARROW PLASMA CELLS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. Giulia Rivoli Received Received
  1410-PS DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT. Romain Gounot Received Received
  1412-PS POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA Cecile Gruchet Received Received
  1413-PS INCIDENCE OF NEGATIVE MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT Carolina Afonso Received Received
  1415-PS SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970-2015: REAL-WORLD DATA FROM A SINGLE CENTER Luis Gerardo Rodríguez-Lobato Received Received
  1421-PS HONEUR (HEAMATOLOGY OUTCOMES NETWORK IN EUROPE) DISTRIBUTED STATISTICS IN A FEDERATED MODEL TO SUPPORT REAL WORLD DATA RESEARCH IN HEMATOLOGY Michel Van Speybroeck Received Received
  1423-PS NEXT-GENERATION SEQUENCING STUDY OF V(D)J REARRANGEMENTS ON NON-CR PATIENTS SHOWING MRD NEGATIVITY BY NEXT-GENERATION FLOW Kim Sung-Min Received Received
  1424-PS THE CRAB SCORE: A SIMPLE PROGNOSTIC TOOL IN MULTIPLE MYELOMA Helena Bean Received Received
  1427-PS THE SIGNIFICANCE OF UNEXPECTED PHARMACOKINETICS OF DARATUMUMAB DURING LONG-TERM MONTHLY TREATMENT FOR MYELOMA Linda Little Received Received
  1432-PS 3-WEEKLY DARATUMUMAB-IMID-DEXAMETHASONE IS HIGHLY EFFICACIOUS, HENCE FINANCIALLY AFFORDABLE WITH ENORMOUS ECONOMIC IMPACT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN LESS AFFLUENT COUNTRIES Eva Hortas Received Received
  1435-PS SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION Shoichiro Kato Received Received
  1436-PS IFN-? TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO. Harini Nivarthi Received Received
  1438-PS DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS Vibe Skov Received Received
  1443-PS BLOCKADE OF TNFR1 RATHER THAN TNFR2 IMPROVES HEMATOCRIT AND REDUCES BLOOD PRO-INFLAMMATORY CYTOKINE LEVELS IN THE VAV1-CRE X JAK2/V617F MPN MOUSE MODEL Peter Mller Received Received
  1447-PS ANALYSIS OF UPR-RELATED GENE EXPRESSION IN CD34 CELLS FROM PATIENTS WITH PRIMARY MYELOFIBROSIS REVEALS DOWNREGULATION OF UPR GENES AND REDUCTION OF APOPTOSIS Paolo Catarsi Received Received
  1452-PS GLI-1, EFFECTOR OF CANONICAL HEDGEHOG SIGNALING PATHWAY, DOES NOT SEEM TO BE DYSREGULATED IN PATIENTS WITH MYELOFIBROSIS Marko Lucijanic Received Received
  1453-PS CURCUMIN INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN JAK2 MUTATED CELLS THROUGH THE INHIBITION OF JAK2/STAT AND MTORC1 PATHWAYS Jessica Petiti Received Received
  1457-PS MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS) Christoph Klade Received Received
  1458-PS RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT Barbara Mora Received Received
  1461-PS FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES Tanasi Ilaria Received Received
  1462-PS SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY Margherita Maffioli Received Received
  1466-PS CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW Olivia Geen Received Received
  1470-PS EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA Veronika Buxhofer-Ausch Received Received
  1472-PS CURRENT PRACTICE IN MANAGEMENT OF ESSENTIAL THROMBOCYTEMIA AND POLYCYTHEMIA VERA: A SURVEY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS (FIM) AMONG 120 HEMATOLOGISTS AND INTERNISTS Mathieu Wemeau Received Received
  1474-PS NON-HODGKIN LYMPHOMA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS Kentaro Yoshinaga Received Received
  1475-PS COATED PLATELET FUNCTION IS RELATED TO BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED THROMBOCYTOPENIA Nanna Broens Received Received
  1476-PS APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS Marian Stevens-Kroef Received Received
  1481-PS PLATELET REACTIVITY AND RESPONSE TO ANTIPLATELET DRUGS IN THROMBOCYTOPENIA AND THROMBOCYTOSIS Lidia Usnarska-Zubkiewicz Received Received
  1488-PS ATYPICAL HAEMOLYTIC URAEMIC SYNDROME IN THE ECULIZUMAB ERA: PRESENTATION, RESPONSE TO TREATMENT AND EVALUATION OF AN ECULIZUMAB WITHDRAWAL STRATEGY Lucy Neave Received Received
  1492-PS ASSESSING TREATMENT RESPONSE IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA WITH AN INNOVATIVE SHEAR FLOW-BASED ASSAY Chiara Vendramin Received Received
  1493-PS NEXT-GENERATION SEQUENCING REVEALS DISTINCT EXPANDED T-CELL RECEPTOR (TCR) B-CHAIN CLONOTYPES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) Amna Malik Received Received
  1495-PS FUNCTIONAL ASSAYS USING WASHED PLATELETS FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS: A RETROSPECTIVE STUDY COMPARING HEPARIN- INDUCED PLATELET ACTIVATION TEST VERSUS 14C-SEROTONIN RELEASE ASSAY Vasiliki GKALEA Received Received
  1497-PS NEUTROPHIL EXTRACELLULAR TRAPS (NETS), BLOOD CELL COUNTS AND THROMBOTIC RISK IN ITP PATIENTS Maria L Lozano Received Received
  1499-PS THE EMOTIONAL IMPACT OF WATCH AND WAIT FOR CLL Lauren Walton Received Received
  1502-PS VALIDATION OF HAND GRIP STRENGTH AS A SCREENING TOOL FOR FRAILTY IN OLDER PATIENTS ON TREATMENT FOR HEMATOLOGIC MALIGNANCIES: THE FRAILTY TASK FORCE STUDY Tommasina Guglielmelli Received Received
  1504-PS ASSESSMENT OF HM-PRO ITALIAN VERSION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN CLINICAL PRACTICE Esther Oliva Received Received
  1506-PS APREPITANT AS ADJUNCT FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH HEMATOLOGIC MALIGNANCY UNDERGOING HIGHLY EMETOGENIC CHEMOTHERAPY: A META-ANALYSIS Feroni Pella Panjaitan Received Received
  1508-PS QUALITY OF LIFE AND PERCEPTION OF HEALTH CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE UK Sophie Wintrich Received Received
  1509-PS QoL IN PATIENTS WITH R/R MULTIPLE MYELOMA DURING IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION AND IXAZOMIB MAINTENANCE THERAPY AND COMPARISON TO THE GENERAL POPULATION Heinz Ludwig Received Received
  1511-PS THE FINANCIAL IMPACT OF ACUTE LEUKAEMIA Lauren Walton Received Received
  1512-PS THE DIAGNOSTIC YIELD OF BONE MARROW BIOPSY IN PATIENTS WITH LIVER FAILURE Thinzar Ko Ko Received Received
  1515-PS PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION Rouslan Kotchetkov Received Received
  1516-PS COST-EFFECTIVENESS OF RISK-STRATIFIED TREATMENT IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA Ayesha Sajjad Received Received
  1517-PS MILD COGNITIVE IMPAIRMENT, HYPOALBUMINEMIA, HIGH CRP AND GASTRO-INTESTINAL ULCER: 4 MARKERS OF FRAILTY WHICH IDENTIFY OLDER PATIENTS WITH MALIGNANT HEMOPATHIES WHO DONT BENEFIT FROM CHEMOTHERAPY VINCENT THIBAUD Received Received
  1520-PS INCENTIVE SPIROMETRY TO PREVENT ACUTE CHEST SYNDROME IN ADULTS WITH SICKLE CELL DISEASE; A MULTICENTER RANDOMIZED CLINICAL TRIAL Charlotte van Tuijn Received Received
  1524-PS WHEN IS A CT NEEDED TO DIAGNOSE ACUTE PULMONARY EMBOLISM IN INDIVIDUALS WITH SICKLE CELL DISEASE Julie Kanter Received Received
  1530-PS POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY Rohtesh Mehta Received Received
  1534-PS EFFICACY AND SAFETY OF STEM CELL MOBILISATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA Catherine Tang Received Received
  1535-PS AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED BY POST-TRANSPLANT IMMUNOTHERAPY WITH NIVOLUMAB AND UNSELECTED AUTOLOGOUS LYMPHOCYTES INFUSION AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA Fabio Guolo Received Received
  1538-PS SAFETY OF HEMATOPOIETIC STEM CELL DONATION. RETROSPECTIVE ANALYSIS OF EARLY POST DONATION FOLLOW UP IN VOLUNTARY DONORS REGISTERED IN DKMS FOUNDATION DONOR CENTER, POLAND Tigran Torosian Received Received
  1541-PS OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BPDCN Muzaffar Qazilbash Received Received
  1548-PS SAFETY AND EFFICACY OF CANNABIDIOL FOR SEVERE ACUTE GRAFT VERSUS HOST DISEASE - A PHASE I/II STUDY Liat Shargian-Alon Received Received
  1551-PS INTENSIVE ORAL CARE CAN REDUCE BLOOD STREAM INFECTION POST NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC HSCT Tatsuya Suwabe Received Received
  1559-PS EFFICACY AND TOXICITY OF SEAM (SEMUSTINE, ETOPOSIDE, CYTARABINE, AND MELPHALAN) CONDITIONING REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA Eva Hortas Received Received
  1561-PS RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS. Issa Khouri Received Received
  1563-PS POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VS. ANTITHYMOCYTE GLOBULIN AS GVHD PROPHYLAXIS FOR MISMATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION Charlotte NYKOLYSZYN Received Received
  1564-PS HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH DETECTABLE DISEASE AT TRANSPLANT Samer Srour Received Received
  1571-PS EVALUATION OF RISK FACTORS OF GVHD FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ? THALASSEMIA MAJOR:10 YEARS FOLLOW-UP IN 568 PATIENTS Wanxia Tan Received Received
  1576-PS ADENOSINE DIPHOSPHATE RECEPTOR GENE (P2Y12) SEQUENCE VARIANTS AMONG SWEDISH, PALESTINIAN AND CONGOLESE INDIVIDUALS Mohammad Asees Received Received
  1578-PS EPIDEMIOLOGY AND RISK ASSESSMENT OF PEDIATRIC VENOUS THROMBOEMBOLISM IN KOREA Jae Min Lee Received Received
  1581-PS COMPLEMENT SYSTEM ANALYSES IN PATIENTS SUSPECTED TO HAVE ATYPICAL HEMOLYTIC UREMIC SYNDROME Jorge Martínez Nieto Received Received
  1582-PS DECREASED PLATELET REACTIVITY IS ASSOCIATED WITH AN INFLAMMATORY STATUS IN PATIENTS WITH CANCER Julia Riedl Received Received
  1586-PS EFFECT OF ORAL ANTICOAGULANT TREATMENT ON THE MORTALITY OF PATIENTS WITH ACUTE HEART FAILURE: ANALYSIS BY PROPENSITY SCORE MATCHING. M ANGELES FERNANDEZ RODRIGUEZ Received Received
  1587-PS EDUCATIONAL INTERVENTION ENCOURAGING APPROPRIATE USE OF BLOOD TRANSFUSIONS EXTENDED FOLLOW UP AND COMPARATIVE STUDY Oren Pasvolsky Received Received
  1588-PS FIBRINOLYSIS IN PATIENTS WITH CHEMOTHERAPY INDUCED THROMBOCYTOPENIA AND THE EFFECT OF PLATELET TRANSFUSION. Floor Heubel-Moenen Received Received
  1592-PS EFFECT OF ANAEMIA ON MUSCLE OXYGEN SATURATION DURING EXERCISE Philip Crispin Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
20:11
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

24th Congress of EHA

 

June 13-16, 2019 Amsterdam
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 22/06/2019 TO 22/06/2019
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.24EHA.2019 




PosterSessionOnline
Logo Draft
 
Logo Cert